NCT00341328View on ClinicalTrials.gov

Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients.

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

March 31, 2012

Conditions
Tuberculosis
Interventions
BIOLOGICAL

Intradermal injection of Mycobacterium w

Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks

Trial Locations (2)

110029

All India Institute of Medical Sciences, New Delhi

282001

Central JALMA Institute of Leprosy and Other Mycobacterial Diseases, Agra

All Listed Sponsors
lead

Ministry of Science and Technology, India

OTHER_GOV

NCT00341328 - Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. | Biotech Hunter | Biotech Hunter